PDLIM7 and lymphoma: BAY11–7085, an inhibitor of NFκB signaling, also greatly decreased the viability of the LMP1 transgenic lymphocytes and lymphoma cells at doses as low as 1 μM, and at 5 μM the cells were completely nonviable (Figure 7).